Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Perrigo Remains Committed To Splitting Off Prescription Despite Delay

Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.

Strategy Sales & Earnings

China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

Deals Strategy

Cipla Sees Muted First Quarter Amid Distributor 'Churn' In India

A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.

Commercial Strategy
See All

Deals Explore this Topic

Set Alert for Deals

Advanz Has Six Deals In The Works As It Cuts Its Losses

Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.

M & A Deals

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Value-Added Medicines Deals

China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

Deals Strategy
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Teligent Prepares For Injectables Filings With Strengthened Team

As it prepares to start injectables filings from its facility in Buena, New Jersey, Teligent is putting in place its senior operational and quality functions. 

United States Business Strategies

Lupin Q1 Profit Up 50% But Regulatory Overhang, Slow Product Scale-Up Sparks Concern

Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Manufacturing Business Strategies

Pooled Data Among AAM’s Concerns On FDA’s Therapeutic Protein Biosimilars Guidance

Three key areas for improvement in in the FDA’s draft guidance on therapeutic protein biosimilars have been highlighted by industry association AAM. Pharmaceutical giants such as Pfizer, Novartis and Celltrion have also expressed concerns highlight shortcomings and sought clarification.

Biosimilars Regulation
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Advanz Has Six Deals In The Works As It Cuts Its Losses

Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.

M & A Deals

Bortezomib Boom Benefits Stada But Pemetrexed Position Proves Perplexing

Launching the oncology drug bortezomib in 14 European countries helped Stada to record an 11% increase in both Generics and group sales in the first half of 2019. But the German group, which is about to start rolling out biosimilar teriparatide, has suffered a legal setback on pemetrexed in its home market.

Sales & Earnings Intellectual Property

Sagent Slides To A Loss, Dragging Down Nichi-Iko’s Margin

An operating loss recorded by its US Sagent affiliate depressed Nichi-Iko’s group operating margin to just 3.7%, even though the Japanese generics specialist’s turnover increased by a tenth on strong domestic generics demand.

Sales & Earnings Japan
See All

People Explore this Topic

Set Alert for People

Teva’s Finance Chief Insists Departure Is Purely Personal

Teva’s finance chief Mike McClellan is leaving the company in November. But he maintains his departure is solely due to personal reasons.

Leadership Israel

People Round-Up: Endo Promotes Ciarico To Head Steriles And Generics

Endo has named a head for its sterile injectables and generics operations; Hikma has appointed an R&D head; Acino has a new leader for its Latin American business; Alvogen has appointed a general counsel; and Julphar has shaken up its senior management team.

 
Appointments Leadership

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Appointments Strategy
See All
UsernamePublicRestriction

Register